Please use this link to access this publication. Abstract Cannabidiol (CBD) has arisen as a promising therapeutic option for children with drug-resistant epilepsy (DRE). CBD has received regulatory nod from different regulatory authorities in the United States, Europe, and India for children with DRE particularly, Dravet syndrome (DS), Lennox Gastaut syndrome (LGS), and Tuberous sclerosis complex (TSC). Recent clinical trials and observational studies highlight the potential of CBD to lower seizure frequency and provide better quality of life in children affected by these disorders. The safety profile is generally favorable with minor common adverse events such as somnolence, diarrhea, and gastrointestinal issues. Furthermore, the...

Abstract As the global population ages, the need for effective interventions to support cognitive health in older adults is growing. Cannabidiol (CBD), a non-intoxicating component of cannabis, has emerged as a potential neuroprotective agent due to its anti-inflammatory, antioxidant, and anxiolytic properties. While preclinical studies show promising effects on hippocampal neurogenesis and cognitive performance, human trials remain limited, particularly in older populations. Existing studies have focused primarily on young, healthy adults and acute administration, often using oral routes that yield low and variable bioavailability. Furthermore, the endocannabinoid system undergoes age-related changes, potentially altering CBD efficacy in older adults. This review synthesizes current evidence on...

Abstract Background: Essential tremor (ET) is characterized by often disabling action tremors. No pharmacological agent has been developed specifically for symptomatic treatment. Anecdotal reports describe tremor improvement with cannabis, but no evidence exists to support these claims. We conducted a phase Ib/II double-blind, placebo-controlled, crossover pilot trial in participants with ET to investigate tolerability, safety, and efficacy of Tilray TN-CT120 LM, an oral pharmaceutical-grade formulation containing tetrahydrocannabinol (THC) 5 mg and cannabidiol (CBD) 100 mg. Our objectives were to determine if short-term THC/CBD exposure improved tremor amplitude and was tolerated. Methods: Participants with ET were randomized (1:1) to receive either TN-CT120 LM or placebo. Dose titration,...

Abstract Cannabidiol (CBD), the main non-intoxicating compound in cannabis, has been hypothesized to reduce the adverse effects of Δ9-tetrahydrocannabinol (THC), the main psychoactive and analgesic component of cannabis. This clinical trial investigated the hypothesis that CBD counteracts the adverse effects of THC and thereby potentially improves the tolerability of cannabis as an analgesic. A randomized, double-blind, placebo-controlled, five-way cross-over trial was performed in 37 healthy volunteers. On each visit, a double-placebo, THC 9 mg with placebo CBD, or THC 9 mg with 10, 30, or 450 mg CBD was administered orally. Psychoactive and analgesic effects were quantified using standardized test batteries. Pharmacokinetic sampling was performed. Data were...

Abstract There is increasing evidence that cannabidiol (CBD) use is associated with clinically significant liver enzyme (LE) elevations and drug-induced liver injury (DILI). The proportion of LE elevations and DILI events reported in the literature meet the Council for International Organizations of Medical Sciences' (CIOMS) classification of a common adverse drug reaction. However, these potential adverse events are unknown to many clinicians and may be overlooked. The increasing use of CBD for both medical and non-medical use necessitates clear direction in the diagnosis and management of CBD-associated hepatotoxicity. To our knowledge, no such clinical guidance currently exists. For people presenting with elevated LEs, CBD...

Abstract Cannabidiol (CBD), a non-psychoactive compound from Cannabis sativa, shows promise as a therapeutic agent for conditions associated with inflammation and oxidative stress, often involving nitric oxide (NO) signaling dysregulation. This review summarizes preclinical and clinical data on CBD’s impact on nitric oxide synthase (NOS) isoforms and NO levels in cardiovascular, neurological, metabolic, and immune systems. Studies suggest that CBD can reduce inflammation-induced inducible NOS (iNOS) expression while maintaining or enhancing endothelial NOS (eNOS)-mediated NO production, leading to decreased oxidative stress, improved endothelial function, and reduced neuroinflammation. The effects of CBD vary based on dose, formulation, timing, and disease state, with potential interactions with metabolites...

Please use this link to access this publication. Abstract Purpose: The purpose of this pilot study was to investigate cannabidiol (CBD) cream’s effects on muscle soreness and performance after exercise. Materials and Methods: This double-blinded, placebo-controlled experiment included 15 men and 13 women (n = 28; mean ± standard deviation age: 23.29 ± 2.54 years) untrained in lower-body resistance training. Participants were randomized into control (NG, n = 9), CBD (CG, n = 9), or placebo (PG, n = 10) groups. Participants completed a lower-body fatigue protocol (FP) consisting of unilateral maximal concentric and eccentric isokinetic muscle actions of the quadriceps and hamstrings (5 sets, 10 repetitions, both legs). CG and...

Please use this link to access this publication. Abstract Background This review aimed to evaluate the therapeutic potential of cannabidiol (CBD) for management of oral disorders, focusing on its effectiveness in treatment (therapy) of orofacial pain, inflammation, and mucosal lesions. Types of Studies Reviewed This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines. A comprehensive search in 5 databases included randomized controlled trials and nonrandomized trials evaluating CBD’s clinical effects on oral disorders. Inclusion criteria were applied independently by 2 reviewers using predefined eligibility parameters. Results Of 4,093 records, 7 studies met inclusion criteria: 6 randomized controlled trials...

Abstract The increasing availability of cannabidiol (CBD) products worldwide has raised concerns about their safety profile; although CBD is generally considered safe, adverse effects have been reported, particularly from overdose. This report describes a rare case of a 26-year-old male who ingested a small amount of CBD gummies (40 mg) and developed marked tachycardia, complete right bundle branch block (CRBBB), and lactic acidosis. The patient presented with nausea and vomiting, heart rate increased from a normal 80 bpm to 165 bpm, 12-lead ECG confirmed CRBBB, and laboratory tests showed elevated lactate levels indicative of type B lactic acidosis without shock or ischemia. Symptoms resolved with supportive care, including intravenous fluids, and the patient's cardiac conduction returned to normal within a week....

Abstract Background Cannabidiol (CBD) is the primary non-psychoactive component of cannabis. Consumption of CBD is increasing rapidly as it is federally legal and widely available in the United States, Europe, Mexico, Canada, and Asia. CBD is gaining traction in medical and biochemical research, though a comprehensive classification of CBD receptor interactions is yet to be elucidated. Methods A comprehensive literature search across PubMed, Web of Science, and Google Scholar identified studies reporting cannabidiol (CBD) interactions with receptors, enzymes, and biological processes. Eligible articles included cell culture, animal model, biochemical, and clinical studies. Findings were thematically synthesized by body system, emphasizing mechanisms and implications for...